Important note: Information in this Q&A was accurate in 2008. The state of the art may have changed since the publication date.I have been on Stocrin and Kivexa for 7 months now. I am a 46 y.o. male.
My cd4 was 209, VL 49,000, cd4% 14. After 7 months my cd4 is 267, VL 0, cd4% 17.
Have also developed seborrheic dermatitis on my face, which is very slow to respond to treatment.
Anything to worry about here?
You are on a standard first line therapy.
The increase from 209 to 267 T cells may seem small, but when you look at T cells, the percentages are more important than the other numbers. The increase from 14% to 17% in impressive.
Even better, the viral load shows an excellent response to therapy.
It's worth noting that T cells change in variable ways when you start medications. Some people will go from zero to 1000 quickly, others will follow a very gradual rise. With only two measurements, I wouldn't be concerned, the trend is in the right direction
I think you are having a good response to your therapy at seven months.
070
ASKD070
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980,2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.